The American Psychiatric Association (APA) recently released a new practice guideline for the pharmacological treatment of alcohol use disorder (AUD). Despite the high prevalence of AUD and its significant public health consequences, patients with this disorder remain undertreated.
The guideline aims to increase physician and public knowledge on the effectiveness and risks of the five medications that may be used for the treatment of AUD: acamprosate, disulfiram, gabapentin, naltrexone, and topiramate.
- Of these five, naltrexone and acamprosate have the best available evidence related to their benefits, and both have minimal side effects. As such, they should be considered the preferred pharmacological options for patients with moderate to severe AUD who want to reduce drinking or achieve abstinence. However, acamprosate should be avoided in patients with significant renal impairment, and naltrexone should be avoided in patients with acute hepatitis or liver failure, or in patients currently taking opioids or who may be expected to take opioids.
- Disulfiram, gabapentin and topiramate are also options for treatment of AUD but should typically be considered after trying naltrexone and acamprosate, unless the patient has a strong preference for one of these medications. Disulfiram is a special case as it does cause a series of adverse reactions if alcohol is consumed within 12 to 24 hours of taking the medication; the reactions include elevated heart rate, flushed skin, headache, nausea, and vomiting. Therefore, disulfiram is suggested only to patients who wish to achieve abstinence from drinking. Patients taking topiramate are at an increased risk of cognitive dysfunction, dizziness, and loss of appetite, whereas patients taking gabapentin may experience fatigue, insomnia, and headache.
While the guideline focuses specifically on evidence-based pharmacological treatments for AUD, it also includes recommendations and suggestions related to psychiatric evaluation of patients with AUD and developing a person-centered treatment plan. Evidence-based psychotherapeutic treatments for alcohol use disorder also play a major role in treatment and peer support groups such as Alcoholics Anonymous, and other 12-step programs can be helpful for many patients. However, specific recommendations related to these treatments are outside the scope of this guideline.
The full guideline, executive summary, and related materials are available here.
- Need for Multiple Naloxone Doses on the Rise
- Association Found Between Non-Cigarette Tobacco Product Use and Future Cigarette Smoking Among Teens
- Sessions Allows More Aggressive Enforcement of Federal Laws Against Marijuana
- Recreational Marijuana Sales Begin in California
- New England States Report Fewer Opioid Overdose Deaths in 2017
- Deaths Rise From Unintentional Drug and Alcohol Overdoses in the Workplace
- Black Americans Hard Hit by Drug Overdoses in Urban Counties
- Rise in Opioid Deaths Contributes to Reduction in U.S. Life Expectancy
- Social Media is Bringing Our Teens Down
- FDA Launches Campaign to Counter Tobacco Promotion
- Cigarette smoking is increasing among Americans with drug problems
- South Carolina Partners with Law Enforcement on Naloxone Program
- National Drug and Alcohol Facts Week® (NDAFW) is coming January 22-28, 2018
- Children of Alcoholics Week 12-18 February 2017
- Aetna Will Waive Co-Pay for Narcan for Some Customers
- People Who Live With Someone Taking Painkillers More Likely to Get Own Rx
- FDA Sends Warning to Distributors of Snortable Chocolate Powder Called “Coco Loko”
- Cashing in Gift Cards to Pay for Opioids Becoming More Common
- Monitoring the Future Survey Results Issued
- St. Louis Police Saving Fewer Lives with Heroin Antidote Amid Stronger Opiates